Published in Hepatitis Weekly, May 15th, 2006
The trial is designed to assess the safety, tolerability, pharmacokinetics (PK) and viral response to treatment with Avi's proprietary NeuGene antisense compound Avi-4065 among healthy volunteers and patients with HCV.
The first phase of this study was reported preliminarily in January 2006 and completed in March 2006. The trial evaluated 31 healthy volunteers who received 14 consecutive days of treatment of Avi-4065 at three dosage levels. Data from the second phase of the study, assessing HCV...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.